Viktor Drvota
CEO @ Karolinska
Stockholm, Sweden
Viktor Drvota is a funding round investor at Karolinska in Stockholm focused on Medical and Biotechnology. Viktor Drvota is the CEO at Karolinska Development AB. Viktor attended Karolinska Institutet.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries Viktor Drvota invests in
Stages Viktor Drvota invests in
Countries Viktor Drvota invests in
Investment Focus
Industry
- Medical 5 (56%)
- Biotechnology 5 (56%)
- Biopharma 4 (44%)
- Health Care 1 (11%)
- Therapeutics 1 (11%)
Stage
- Funding Round 3 (33%)
- Seed 2 (22%)
- Series B 1 (11%)
- Private Equity 1 (11%)
- Post-IPO Equity 1 (11%)
Country
- Sweden 3 (33%)
- Denmark 3 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BOOST Pharma
|
BOOST Pharma is a biotechnology research company developing a stem cell therapy for the treatment of osteogenesis imperfecta. It is based on novel mesenchymal stem cells that have high bone-forming capabilities that migrate to the bone of patients where they will engraft, and start bone formation.It was founded in 2019 and is headquartered inCopenhagen, Denmark. | Venture - Series Unknown / May 28, 2024 | |
OssDsign
|
OssDsign was founded in May 2011 by Professor Håkan Engqvist, Dr Thomas Engstrand, Bo Qwarnstrom, Jonas Åberg, Uppsala University AB and other leading clinical, preclinical and materials researchers and engineers. The key people in the company are presented below. OssDsign has in addition developed a network of international experts in ClinicalAffairs, Regulatory and Business Development. | $6.2M / Post-IPO Equity / Nov 29, 2022 | |
Henlez
|
Henlez uses precise enzymes to create disruptive topical treatments for recurrent follicular skin problems. The company can be reached via mail, phone, or physical address. | $988.4K / Seed / Oct 24, 2022 | |
AnaCardio
|
AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure. | Seed / Jun 17, 2021 | |
|
OssDsign
|
OssDsign was founded in May 2011 by Professor Håkan Engqvist, Dr Thomas Engstrand, Bo Qwarnstrom, Jonas Åberg, Uppsala University AB and other leading clinical, preclinical and materials researchers and engineers. The key people in the company are presented below. OssDsign has in addition developed a network of international experts in ClinicalAffairs, Regulatory and Business Development. | $10.5M / Nov 04, 2015 | |
InDex Pharmaceuticals
|
InDex Pharmaceuticals AB is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its TLR platform (toll-like receptors). It discovers and develops DIMS drugs (DNA-based immunomodulatory sequence) to treat diseases within a variety of therapeutic areas, including inflammation and cancer. | $20M / Feb 25, 2014 | |
Nuevolution
|
Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics® enables rapid synthesis andDNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing drug discovery technologies. Nuevolutions library collection currently exceeds 1 billion small molecule compounds and synthetic biologics for screening. Nuevolution partners its technology with pharmaceutical and biotechnology companies. Nuevolution has entered into agreementswith Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis Pharma and Boehringer Ingelheim. Nuevolution has also entered into a joint venture consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) aiming at discovery and development of novel small molecule drugs against epigenetic factors. This $ 4 million budget project is supported by the Danish High Technology Fund. Nuevolution has demonstrated the power of Chemetics® by identifying highly potent and drug like novel ligands with the potential toaddress major unmet medical needs across a range of therapeutic areas and target classes. Nuevolution is a privately owned company by key Scandinavian investors, including Industrifonden, SEB Venture Capital, SunstoneCapital, SLS Invest and Novo A/S. | $12.1M / Jun 19, 2012 | |
|
InDex Pharmaceuticals
|
InDex Pharmaceuticals AB is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its TLR platform (toll-like receptors). It discovers and develops DIMS drugs (DNA-based immunomodulatory sequence) to treat diseases within a variety of therapeutic areas, including inflammation and cancer. | $7.2M / Private Equity / Jan 21, 2011 | |
|
Nuevolution
|
Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics® enables rapid synthesis andDNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing drug discovery technologies. Nuevolutions library collection currently exceeds 1 billion small molecule compounds and synthetic biologics for screening. Nuevolution partners its technology with pharmaceutical and biotechnology companies. Nuevolution has entered into agreementswith Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis Pharma and Boehringer Ingelheim. Nuevolution has also entered into a joint venture consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) aiming at discovery and development of novel small molecule drugs against epigenetic factors. This $ 4 million budget project is supported by the Danish High Technology Fund. Nuevolution has demonstrated the power of Chemetics® by identifying highly potent and drug like novel ligands with the potential toaddress major unmet medical needs across a range of therapeutic areas and target classes. Nuevolution is a privately owned company by key Scandinavian investors, including Industrifonden, SEB Venture Capital, SunstoneCapital, SLS Invest and Novo A/S. | $15M / Series B / Oct 10, 2003 |
Co-Investors
Industrifonden
4 deals together
EIR Ventures
1 deal together
Karolinska
1 deal together
Lancelot Asset Management
1 deal together
About Karolinska
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
Karolinska Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Viktor Drvota
CEO
|
|||
Viktor Drvota
CEO
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Viktor Drvota invest in?
Viktor Drvota invests primarily in Medical, Biotechnology and Biopharma startups, most often at Funding Round and Seed stage. Most of the 9 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Viktor Drvota last invest?
The most recent investment recorded for Viktor Drvota closed in May 2024. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
